‹ Screener

Arcturus Therapeutics Holdings Inc.

ARCT · Pharmaceutical Preparations · 28.4M shares · +0%/yr ↑ dilution · EDGAR filings ↗

Reference price $16.56 · est. market cap ~$471M — last insider purchase, 2025-08-15 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)

Grade

D44

Clinical/early-stage biotech — mRNA clinical, heavy burn, funded.

Strengths

Risks

Notable findings

Quarterly revenue

2025-06-30 · $28M2025-09-30 · $17M2025-12-31 · $7M2026-03-31 · $2M

Last 4 quarters · from SEC filings.

Key metrics

Operating margin
-93.0%
Net margin
-80.2%
Return on equity
-30.7%
Return on assets
-24.3%
Revenue growth (QoQ)
-71.4%
Current ratio
6.6×
Free cash flow
-$75M
EBITDA
-$73M
Tangible book value
$214M
Cash & investments
$231M
Cash runway
12q
Stock comp / revenue
31.0%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2025-08-15SASSINE ANDYBuy1.2K$16.56
2025-08-15SASSINE ANDYBuy1.2K$16.56

All non-derivative Form 4 activity (SEC), newest first.

Notable events (8-K)

DateItems
2026-06-05Shareholder votefiling ↗
2026-05-07ResultsExec/director changeReg FDExhibitsfiling ↗
2026-03-03ResultsExhibitsfiling ↗
2025-12-15Exec/director changeExhibitsfiling ↗
2025-11-10ResultsExhibitsfiling ↗
2025-10-22Reg FDOtherExhibitsfiling ↗
2025-09-26Reg FDExhibitsfiling ↗
2025-08-29Reg FDExhibitsfiling ↗

Recent filings

FormFiledPeriodAccession
8-K2026-06-052026-06-050001193805-26-000770 ↗
10-Q2026-05-072026-03-310001193125-26-211943 ↗
8-K2026-05-072026-05-010001193805-26-000573 ↗
10-K2026-03-032025-12-310001193125-26-088391 ↗
8-K2026-03-032026-03-030001193805-26-000214 ↗
8-K2025-12-152025-12-110001193805-25-001734 ↗
10-Q2025-11-122025-09-300001193125-25-275758 ↗
8-K2025-11-102025-11-100001193805-25-001555 ↗
8-K2025-10-222025-10-220001193805-25-001499 ↗
8-K2025-09-262025-09-260001193805-25-001368 ↗
8-K2025-08-292025-08-290001193805-25-001247 ↗
10-Q2025-08-112025-06-300000950170-25-106560 ↗